Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena

October 03, 2025 01:47:03 pm

Source: SeekingAlpha

2025-10-03 13:47:03 ET

Thesis

Structure Therapeutics Inc. (GPCR) is a clinical-stage biotechnology company focused on obesity linked drug developments. It is a GLP-1 oral pure play trying to access one of today’s largest and fastest-growing segments in the pharma industry. Well-known as anti-obesity drugs, the sector is also widely recognized by its leaders—Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO)—and their famous and very successful weight-loss and diabetes drugs Zepbound/Mounjaro and Ozempic/Wegovy, respectively....

Read the full article on Seeking Alpha

For further details see:

Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena